Category - Developments

Developments

PharmaJet’s Needle-free Injection System selected for DNA immunotherapy in advanced melanoma

Closely held PharmaJet announced that its partner, Scancell, has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma demonstrating a progression-free survival (PFS) rate of 74%...

January 9, 2026

Developments

Autonomix highlights data showing pain relief observed in all stages of pancreatic cancer

Autonomix Medical (NASDAQ: AMIX) has announced new subgroup clinical data from its proof-of-concept study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable, and meaningful pain...

January 9, 2026

Developments

Athira announces name change to LeonaBio with new ticker LONA

Athira Pharma (NASDAQ: ATHA) has announced that it has changed its name to LeonaBio (NASDAQ: LONA) effective January 12, 2026, to align with its acquisition of rights to develop and commercialize lasofoxifene, a late...

January 9, 2026

Developments

Day One acquires Mersana and expands pipeline

Day One Biopharmaceuticals (NASDAQ: DAWN) has announced the completion of all conditions of its tender offer to acquire all outstanding shares of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus one...

January 7, 2026

Developments

Actuate announces positive Phase 1 elraglusib results in pediatric cancer

Actuate Therapeutics (NASDAQ: ACTU) has announced results from the phase 1 portion of its Actuate-1902 Phase 1/2 clinical study evaluating elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus...

January 7, 2026

Developments

YD Bio enters MOU to merge with EG BioMed

YD Bio (NASDAQ: YDES) has announced that it has entered into a Memorandum of Understanding (MOU) to merge with closely held EG BioMed—a biotechnology company specializing in DNA methylation–based cancer diagnostics and...

January 7, 2026

Developments

First patient dosed in Akebia’s Phase 2 trial of praliciguat in FSGS

Akebia Therapeutics (NASDAQ: AKBA) has announced that the first patient has been dosed in its Phase 2 clinical trial of praliciguat, an oral once-daily soluble guanylate cyclase stimulator being evaluated for the...

January 7, 2026

Developments

Johns Hopkins Medicine treats first commercial TULSA-PRO case; Profound marks major milestone as hospital launches iMRI suite to expand access to advanced prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company’s TULSA-PRO system. The milestone marks the...

January 6, 2026

Developments

Polyrizon reports positive preclinical results of PL-14 vs HPMC

Polyrizon (NASDAQ: PLRZ) has announced new results from a preclinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an...

January 5, 2026

Developments

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

MetaVia (NASDAQ: MTVA) has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual...

January 5, 2026

Category - Developments

Subscribe